Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Eisen

Showing results (41-50 of 116) with videos related to

Pageof 12
Sort By:
BMJ Case Reports|June 21, 2011
A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinibMark Tuthill, Ravi Barod, Linda Pyle, et al.
Journal of the National Cancer Institute|January 12, 2012
Targeted therapies for renal cell carcinoma: review of adverse event management strategiesTim Eisen, Cora N Sternberg, Caroline Robert, et al.
Lung Cancer (Amsterdam, Netherlands)|April 3, 2007
Lack of evidence that p53 Arg72Pro influences lung cancer prognosis: an analysis of survival in 619 female patientsAthena Matakidou, Rachid El Galta, Emily L Webb, et al.
Lung Cancer (Amsterdam, Netherlands)|October 20, 2006
The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancerUdai Banerji, Sue Ashley, Jim Coward, et al.
Cancer|October 29, 2009
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanomaTim Eisen, Uwe Trefzer, Anne Hamilton, et al.
BJU International|February 12, 2005
Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinomaSarbjinder S Sandhu, Andrew Symes, Roger A'Hern, et al.
Immunology|January 16, 2010
The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cellsLa'Verne P Rennalls, Thomas Seidl, James M G Larkin, et al.
BMC Cancer|July 19, 2020
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UKRobert Hawkins, Kate Fife, Michael Hurst, et al.
Human Molecular Genetics|June 28, 2014
An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinomaLucy Gossage, Douglas E V Pires, Álvaro Olivera-Nappa, et al.
Human Molecular Genetics|September 15, 2007
Genetic variation in the DNA repair genes is predictive of outcome in lung cancerAthena Matakidou, Rachid el Galta, Emily L Webb, et al.
Pageof 12

Showing results (41-50 of 116) with videos related to

Sort By:
Pageof 12
BMJ Case Reports|June 21, 2011
A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinibMark Tuthill, Ravi Barod, Linda Pyle, et al.
Journal of the National Cancer Institute|January 12, 2012
Targeted therapies for renal cell carcinoma: review of adverse event management strategiesTim Eisen, Cora N Sternberg, Caroline Robert, et al.
Lung Cancer (Amsterdam, Netherlands)|April 3, 2007
Lack of evidence that p53 Arg72Pro influences lung cancer prognosis: an analysis of survival in 619 female patientsAthena Matakidou, Rachid El Galta, Emily L Webb, et al.
Lung Cancer (Amsterdam, Netherlands)|October 20, 2006
The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancerUdai Banerji, Sue Ashley, Jim Coward, et al.
Cancer|October 29, 2009
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanomaTim Eisen, Uwe Trefzer, Anne Hamilton, et al.
BJU International|February 12, 2005
Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinomaSarbjinder S Sandhu, Andrew Symes, Roger A'Hern, et al.
Immunology|January 16, 2010
The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cellsLa'Verne P Rennalls, Thomas Seidl, James M G Larkin, et al.
BMC Cancer|July 19, 2020
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UKRobert Hawkins, Kate Fife, Michael Hurst, et al.
Human Molecular Genetics|June 28, 2014
An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinomaLucy Gossage, Douglas E V Pires, Álvaro Olivera-Nappa, et al.
Human Molecular Genetics|September 15, 2007
Genetic variation in the DNA repair genes is predictive of outcome in lung cancerAthena Matakidou, Rachid el Galta, Emily L Webb, et al.
Pageof 12